All NICE products on oesophageal cancer. Includes any guidance and quality standards.

At its meeting today (25 September 2024) NICE’s Board concluded the new severity modifier is working as intended and is ...

An insight into one of NICE’s most long-standing collaborative relationships. For nearly 20 years, NICE has worked with the ...

Evidence from current practice provided by NHS England and analysed by NICE indicates that digital therapies recommended for PTSD could save over 5,000 hours of therapist time per 1,000 people. Almost ...

If you’re commenting for an organisation, your organisation needs to be registered as a stakeholder before we can accept comments. Not eligible to be a stakeholder? Contact the stakeholder ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

Cookies are files saved on your phone, tablet or computer when you visit a website. We use cookies to store information about how you use the NICE website and services, such as the pages you visit.

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

There is a simple discount patient access scheme for rucaparib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Rucaparib is recommended, within its marketing authorisation, as an option for the maintenance treatment of relapsed platinum-sensitive high-grade epithelial, ovarian, fallopian tube or primary ...

A list of downloadable documents created during development.